Is insufficient blood supply to the heart easy to cure? What are the methods?

Sometimes internal organ mutations in the heart can cause poor blood circulation, or adverse mental changes in the patient or even climate changes can lead to coronary artery spasms, resulting in insufficient blood supply to the myocardium. Insufficient blood supply to the heart can cause chest tightness, palpitations and other discomforts in mild cases, while severe cases can lead to angina pectoris, coronary heart disease and other diseases. If there is insufficient blood supply to the heart, you should pay attention to it and seek medical treatment promptly.

Insufficient blood supply to the heart can be cured by treatment. It is generally divided into drug treatment and surgical treatment. Drug treatment includes coronary dilation, blood circulation, and anticoagulation therapy. Surgical treatment involves doing a cardiac angiography and placing a stent in the narrowed section of the blood vessel.

In recent years, with the continuous progress of diagnosis and treatment technologies for coronary heart disease, especially the publication of the results of large-scale evidence-based medicine trials, reasonable and effective intervention measures have been continuously applied in clinical practice. The following is a brief introduction to modern treatments for coronary heart disease.

Percutaneous coronary intervention for coronary heart disease

The world's first percutaneous transluminal coronary angioplasty (PTCA) was performed in 1977. In the early stages of interventional treatment, balloon dilatation was the main method used to treat coronary artery stenosis, which to a certain extent relieved the angina symptoms of patients with coronary heart disease. However, the problem of vascular restenosis after PTCA is serious, and some patients experience dissection tearing or even acute vascular occlusion during the operation. The advent of coronary artery stents was a milestone, as their placement reduced restenosis and the need for surgical bypass surgery. However, there is still a 10% to 20% incidence of restenosis after stent implantation, and it is even more difficult to treat in-stent restenosis. Intravascular brachytherapy, which has emerged in recent years, is effective for in-stent restenosis, but there are still some problems, such as late thrombosis, edge effect, aneurysmal changes, and operator protection. The emergence of drug-eluting stents is another milestone in the treatment of coronary heart disease. Its advent provides us with a new weapon to conquer vascular restenosis. Recent studies have shown that rapamycin and paclitaxel-coated stents can prevent rather than delay restenosis in blood vessels.

Lipid-lowering therapy for coronary heart disease

Lipid-lowering drugs are very important in the treatment of coronary heart disease. Many large-scale clinical trials have confirmed that statins can significantly reduce the incidence of non-fatal myocardial infarction and major cardiovascular events. The US ATP-III guidelines have set the cholesterol treatment target at 2.6mmol/L (100mg/dl). The guidelines emphasize that various risk factors should be controlled comprehensively according to the risk level of coronary heart disease. Intensive statin therapy has shown potential therapeutic benefits in patients undergoing both PCI and coronary artery bypass grafting (CABG). Statins play a very important role in delaying atherosclerosis, reducing adverse coronary events, and lowering the disability rate of patients with coronary heart disease. In particular, statins combined with coronary artery disease intervention or surgical bypass surgery have a more significant effect on improving patients' clinical prognosis.